Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent

1. A compound represented by Formula 1:

wherein

A is selected from a substituent of Formula 2:

wherein

R 1 is hydrogen or CF 3 , and

R 2 is selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 3 -C 10 cycloalkyl, substituted or unsubstituted C 3 -C 10 heterocycloalkyl, substituted or unsubstituted C 4 -C 8 aryl and substituted or unsubstituted C 3 -C 7 heteroaryl; and

a substituent of Formula 3:

wherein R 3 is selected from the group consisting of hydrogen, halogen, and substituted or unsubstituted C 1 -C 4 alkyl; and

B is selected from the group consisting of a substituent of Formula 4:

wherein

X is —CR 4 R 5 — or —CO—, wherein R 4 and R 5 are each independently hydrogen or hydroxy, provided that at least one of R 4 and R 5 is hydroxy,

R 6 , R 7 , R 8 and R 9 are each independently selected from the group consisting of hydrogen, halogen and substituted or unsubstituted C 1 -C 4 alkyl, and

n is 0 or 1;

a substituent of Formula 5:

wherein

X is —CR 10 R 11 — or —CO—, wherein R 10 and R 11 are each independently hydrogen or hydroxy, provided that at least one of R 10 and R 11 is hydroxy,

R 12 , R 13 and R 14 are each independently selected from the group consisting of hydrogen, halogen and substituted or unsubstituted C 1 -C 4 alkyl, and

Y is oxygen or sulfur;

a substituent of Formula 6:

wherein

X is —CR 15 R 16 — or —CO—, wherein R 15 and R 16 are each independently hydrogen or hydroxy, provided that at least one of R 15 and R 16 is hydroxy,

Z is —CH— or oxygen, provided that when Z is oxygen, R 19 is absent, and

R 17 , R 18 and R 19 are each independently selected from the group consisting of hydrogen, halogen, and substituted or unsubstituted C 1 -C 4 alkyl; and

a substituent of Formula 7:

wherein

X is —CR 20 R 21 — or —CO—, wherein R 20 and R 21 are each independently hydrogen or hydroxy, provided that at least one of R 20 and R 21 is hydroxy, and

R 22 is substituted or unsubstituted C 1 -C 4 alkyl; or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein when the alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is substituted, the substituent is C 1 -C 10 alkyl or halogen.

3. The compound according to claim 2 , wherein the halogen is fluorine.

4. The compound according to claim 1 , wherein A in Formula 1 is a substituent represented by Formula 2 wherein R 1 is hydrogen or CF 3 , and R 2 is selected from the group consisting of hydrogen, and C 1 -C 5 alkyl, C 3 -C 6 cycloalkyl, C 3 -C 10 heterocycloalkyl, C 4 -C 8 aryl and C 3 -C 7 heteroaryl, each of which is optionally substituted by halogen.

5. The compound according to claim 4 , wherein when R 2 is unsubstituted or halogen-substituted C 3 -C 10 heterocycloalkyl or unsubstituted or halogen-substituted C 3 -C 7 heteroaryl, the heterocycloalkyl or heteroaryl is any one selected from the group consisting of furan, thiophene, pyrrole, pyrrolidine, imidazole, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazolidine, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, pyridine, pyridinone, pyridazine, pyrazine, pyrimidine, piperidine, piperazine, morpholine, pyridazinone, tetrazole, triazole, triazolidine and azepine.

6. The compound according to claim 4 , wherein R 2 is selected from the group consisting of trifluoromethyl, propyl, butyl, t-butyl, cyclobutyl, pyridine, furan, methoxyethyl, thiophene and 4-fluorophenyl.

7. The compound according to claim 1 , wherein B in Formula 1 is a substituent represented by Formula 4 wherein X is —(CH—OH)—or —CO—, R 6 and R 7 are each independently selected from the group consisting of hydrogen, fluoro and unsubstituted C 1 -C 4 alkyl, and R 8 and R 9 are each independently hydrogen.

8. The compound according to claim 1 , wherein the compound is a compound of Formula 1a:

wherein A and B are as defined for Formula 1.

9. The compound according to claim 1 , wherein the compound is any one of the following compounds:

1-[(2S)-amino-4-(2,4-bis-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-4-oxo-butyl]-5,5-difluoro-(6R)-hydroxy-piperidin-2-one,

1-[(2S)-amino-4-(2,4-bis-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-4-oxo-butyl]-5,5-difluoro-(6S)-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-oxo-4-(2-propyl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-butyl]-5,5-difluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-(2-t-butyl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-4-oxo-butyl]-5,5-difluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-(2-cyclobutyl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-4-oxo-butyl]-5,5-difluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-oxo-4-(2-pyridin-4-yl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-butyl]-5,5-difluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-(2-furan-2-yl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-butyl]-4-oxo-butyl]-5,5-difluoro-6-hydroxy-piperidin-2-one,

1-{(S)-2-amino-4-[2-(2-methoxy-ethyl)-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxo-butyl}-5,5-difluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-oxo-4-(2-thiophen-3-yl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-butyl]-5,5-difluoro-6-hydroxy-piperidin-2-one,

1-{(S)-2-amino-4-[2-(4-fluoro-phenyl)-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxo-butyl}-5,5-difluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-(2,4-bis-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-4-oxo-butyl]-3,3-difluoro-piperidine-2,6-dione,

1-[(S)-2-amino-4-(2-t-butyl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-4-oxo-butyl]-5-fluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-(2-furan-2-yl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-4-oxo-butyl]-5-fluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-oxo-4-(2-thiophen-3-yl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-butyl]-5-fluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-oxo-4-(2-propyl-5-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-butyl]-5-fluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-oxo-4-(2-pyridin-4-yl-5-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-butyl]-5-fluoro-6-hydroxy-piperidin-2-one,

1-[(S)-2-amino-4-oxo-4-(2-thiophen-3-yl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-butyl]-3-methyl-piperidine-2,6-dione, and

1-[(S)-2-amino-4-(2-t-butyl-4-trifluoromethyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidin-7-yl)-4-oxo-butyl]-3-methyl-pyrrolidine-2,6-dione.

10. A pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) comprising a compound of Formula 1 of claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, diluent or excipient, or any combination thereof.

11. The pharmaceutical composition according to claim 10 , wherein the pharmaceutical composition is formulated for treating a DPP-IV-related disease.

12. The pharmaceutical composition according to claim 11 , wherein the DPP-IV-related disease is diabetes or obesity.